By leveraging our advanced technology platform, Creative Biolabs has established a novel platform to engineer B cells for anti-leukemia antibody delivery covering a wide range of research hotpots, which will help clients to meet these research needs.
Leukemia is a generic term for cancers of the bone marrow and lymphatic system. Leukemia is the most common disease in adults over 55 years old, while it is also the most often cancer in children under 15 years old. There are four main types of leukemia, each named for the rate at which the disease progresses and worsens as well as the blood cell type affected.
Fig.1 Leukemia types. (Creative Biolabs)
With the rapid development of research and therapy, there are currently several targeted antibody immunotherapy regimens for leukemia.
Fig.2 Targeted antibody immunotherapy regimens for
leukemia. (Creative Biolabs)
With progress in both targeted therapies and immunotherapies, leukemia treatment has the potential to become more effective and less toxic. Currently, we have established a platform to engineer B cells for anti-leukemia antibody delivery. We provide several genetic engineering strategies in which genetic editing was used to replace endogenously encoded antibodies with antibodies targeting leukemia targets in B cells. This approach will greatly facilitate the customer's further research focused on leukemia treatment.
Creative Biolabs develops and commercializes a full range of one-stop solutions for B Cell engineering for our customers. With advanced technologies and a professional academic team, Creative Biolabs makes it easy to advance your project successfully. Please feel free to contact us for more information.